The risks of overusing short-acting beta(2)-agonists (SABA), including an increase in asthma-related deaths, are many and well known. The Global Initiative on Asthma (GINA) 2019 and 2020 updates recommend as-needed inhaled corticosteroid (ICS)/formoterol as the preferred rescue medication in mild asthma as monotherapy and also in moderate to severe asthma when the maintenance and reliever therapy (MART) strategy is used. Using SABA for symptom relief, however, was the standard of treatment for many years, and consequently this practice persists, particularly in patients not taking ICS regularly. Here, we examine the rationale for this shift from a long-standing recommendation for as-needed SABA treatment to the use of as-needed ICS/formoterol and consider clinical evidence on strategies for asthma treatment and patient management.

Canonica, G. W., Paggiaro, P., Blasi, F., Musarra, A., Richeldi, L., Rossi, A., Papi, A., Manifesto on the overuse of SABA in the management of asthma: new approaches and new strategies, <<THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE>>, 2021; 15 (15): 17534666211042534-17534666211042539. [doi:10.1177/17534666211042534] [http://hdl.handle.net/10807/187363]

Manifesto on the overuse of SABA in the management of asthma: new approaches and new strategies

Richeldi, Luca;
2021

Abstract

The risks of overusing short-acting beta(2)-agonists (SABA), including an increase in asthma-related deaths, are many and well known. The Global Initiative on Asthma (GINA) 2019 and 2020 updates recommend as-needed inhaled corticosteroid (ICS)/formoterol as the preferred rescue medication in mild asthma as monotherapy and also in moderate to severe asthma when the maintenance and reliever therapy (MART) strategy is used. Using SABA for symptom relief, however, was the standard of treatment for many years, and consequently this practice persists, particularly in patients not taking ICS regularly. Here, we examine the rationale for this shift from a long-standing recommendation for as-needed SABA treatment to the use of as-needed ICS/formoterol and consider clinical evidence on strategies for asthma treatment and patient management.
2021
Inglese
Canonica, G. W., Paggiaro, P., Blasi, F., Musarra, A., Richeldi, L., Rossi, A., Papi, A., Manifesto on the overuse of SABA in the management of asthma: new approaches and new strategies, <<THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE>>, 2021; 15 (15): 17534666211042534-17534666211042539. [doi:10.1177/17534666211042534] [http://hdl.handle.net/10807/187363]
File in questo prodotto:
File Dimensione Formato  
MANIFESTO.pdf

accesso aperto

Licenza: Creative commons
Dimensione 144.67 kB
Formato Adobe PDF
144.67 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/187363
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 7
social impact